Optimizing Bruton Kinase (BTK) Inhibitors in Relapsed/Refractory (R/R) Mantle Cell Lymphoma

Kami Maddocks, MD, and Alexey Danilov, MD, PhD, discuss the use of Bruton tyrosine kinase (BTK) inhibitors for the treatment of relapsed/refractory mantle cell lymphoma.

EP. 1: Overview of Mantle Cell Lymphoma

May 31st 2023

Kami Maddocks, MD, and Alexey Danilov, MD, PhD, provide an overview of mantle cell lymphoma, including prevalence and common risk factors.

EP. 2: Common Frontline Therapy Approaches for Patients With Mantle Cell Lymphoma

May 31st 2023

Drs Kami Maddocks and Alexey Danilov review the frontline therapy options for patients with mantle cell lymphoma based on risk status.

EP. 3: Role of Maintenance Therapy in Newly Diagnosed Mantle Cell Lymphoma

July 20th 2023

Experts explain the role of maintenance therapy in mantle cell lymphoma and how it impacts the risk of disease progression.

EP. 4: Bruton Kinase Inhibitors for Relapsed/Refractory Mantle Cell Lymphoma

July 20th 2023

Kami Maddocks, MD, and Alexey Danilov, MD, PhD, discuss the evolution of BTK inhibitors and how they have changed treatment approaches in clinical practice.

EP. 5: Data on Covalent BTK Inhibitors for the Treatment of R/R Mantle Cell Lymphoma

July 28th 2023

Drs Kami Maddocks and Alexey Danilov review data from ongoing studies evaluating covalent BTK inhibitors in relapsed/refractory mantle cell lymphoma.

EP. 6: Evaluating Pirtobrutinib in Patients with R/R Mantle Cell Lymphoma

July 28th 2023

Experts discuss data on pirtobrutinib, a non-covalent BTK inhibitor, in the treatment of patients with relapsed/refractory mantle cell lymphoma.

EP. 7: Future Directions in the Treatment of Mantle Cell Lymphoma

August 3rd 2023

Kami Maddocks, MD, and Alexey Danilov, MD, PhD, close their discussion with a look at the future treatment landscape of mantle cell lymphoma.